Approved for the treatment of active SJIA in patients 2 years and olderSafety and effectiveness in pediatric patients with conditions other than SJIA have not been establishedChildren < 2 years have not been studiedInterruption of dosing may be needed for management of dose-related laboratory abnormalities including elevated liver enzymes, neutropenia, and thrombocytopeniaLiver enzyme elevation, low neutrophil count, low platelet count and lipid elevations are noted with Actemra treatment in the SJIA population. The most common adverse events Actemra treated patients in the controlled portion of the study were upper respiratory tract infection, headache, nasopharygitis and diarheaInformation on dosing, lab parameters, adverse reactions, clinical trialNew indication
|